摘要
目的分析耐多药肺结核患者服用抗结核药物后的不良反应发生状况。方法从本院2014 年1 月—2018 年1 月接受的耐多药肺结核患者中,抽取91 例作为研究对象,所有患者均按照中国全球基金耐多药肺结核项目第七轮治疗治方案相关标准进行治疗,观察患者不良反应发生率和具体表现。结果耐多药肺结核患者服用抗结核药物治疗后可引起患者诸多系统发生不良反应,其中以肝胆系统不良反应发生率最高约占30.77%,其次是其次是胃肠道27.47%,皮肤系统19.78%以及血液系统16.48%。结论耐多药肺结核患者服用抗结核药物后不良反应较多,在治疗过程中要密切监测患者血液、肝肾功能、皮肤状况等,及时发现并给应相应的处理,以提高患者生存质量。
Objective Analysis of adverse reactions of multidrug-resistant pulmonary tuberculosis patients after taking antituberculosis drugs. Method From January 2014 to January 2018, 91 patients with MDR-TB were selected as the study subjects. All patients were treated according to the relevant standards of the 7th Round Treatment Program of China Global Fund MDR-TB Project. The incidence and specific manifestations of adverse reactions were observed. Result MDR-TB patients taking antituberculosis drugs can cause many systemic adverse reactions, among which the highest incidence of adverse reactions in liver and gallbladder system is about 30.77%, followed by gastrointestinal tract 27.47%, skin system 19.78% and blood system 16.48%. Conclusion Patients with MDRTB have more adverse reactions after taking anti-TB drugs. In the course of treatment, blood, liver and kidney function, skin condition and so on should be closely monitored, and timely detection and corresponding treatment should be given to improve the quality of life of patients.
作者
公维亮
GONG Weiliang(Department of Tuberculosis, Weifang Second People's Hospital, Weifang Shandong 261041,China)
出处
《中国继续医学教育》
2019年第30期136-138,共3页
China Continuing Medical Education
关键词
耐多药
肺结核
抗结核药物
不良反应
发生率
表现
multi drug resistant
pulmonary tuberculosis
antituberculosis drugs
side effects
incidence rate
performance
